Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Launch innovative vitamin sublingual sprays
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Subscribe To Our Newsletter & Stay Updated
